Compare KLTR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | ELDN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.6M | 208.6M |
| IPO Year | 2021 | 2014 |
| Metric | KLTR | ELDN |
|---|---|---|
| Price | $1.52 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.50 | ★ $8.50 |
| AVG Volume (30 Days) | 293.9K | ★ 705.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $178,717,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $1.08 | N/A |
| P/E Ratio | $21.64 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $1.21 | $1.35 |
| 52 Week High | $2.29 | $4.60 |
| Indicator | KLTR | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 69.96 |
| Support Level | $1.39 | $2.48 |
| Resistance Level | $1.68 | $2.77 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 88.41 | 92.31 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.